Home / People / Dr. Jörn Witt
Portrait ofJörn Witt

Dr. Jörn Witt, LL.M. (University of London)

Partner
Rechtsanwalt

CMS Hasche Sigle
Stadthausbrücke 1-3
20355 Hamburg
Germany
Languages English

Jörn Witt focuses on the lifesciences and agrosciences sector and advises pharmaceutical companies, medical device manufacturers, agroscience companies as well as companies in related regulated industries. He covers regulatory and reimbursement matters and also assists his clients with drafting and negotiating cooperation and development agreements for business development purposes. Jörn furthermore represents his clients in contentious cases and regularly advises on transactions in the life sciences sector.

Jörn’s practice covers licensing and pharmaceutical law as well as drugs and medical devices advertising law. He also advises his clients on statutory health insurance law issues, in particular in the context of new forms of care, and on crop protection law. Across all industries, Jörn furthermore advises on intellectual property matters with a focus on trademark and competition law as well as anti-counterfeiting campaigns.

He joined CMS in 2006 and has been a partner since 2013.

more less

„Oft empfohlen“ für Gesundheitswesen

JUVE Handbuch, 2023/2024

Listed for Pharmaceutical Law

Deutschlands beste Anwälte 2023 – Handelsblatt in Kooperation mit Best Lawyers

Listed for Intellectual Property

Deutschlands beste Anwälte 2023 – Handelsblatt in Kooperation mit Best Lawyers

"Jörn Witt: High quality standards. High level of commitment and dedication. Always maintains an overview in order to set priorities correctly. Very experienced, professional and approachable.", client

The Legal 500 EMEA, 2023

"The team behind leadership duo Thomas Manderla in Düsseldorf and Jörn Witt in Hamburg […] impresses with broad sector expertise"

The Legal 500 EMEA, 2021

"Recommended" for Pharmaceuticals and Healthcare

JUVE German Commercial Law Firms 2022 (GCLF)

"reliable, competent", "very knowledgeable and experienced, makes a huge contribution to strategies in legal disputes, excellent wing man who protects his own advances", clients

JUVE German Commercial Law Firms 2022 (GCLF)

"Jörn Witt is committed, professional, experienced and reliable.", client

The Legal 500 EMEA, 2022

Publications

  • Unlautere Nachahmung eines Medizinproduktes – Femur-Teil, zugleich Anmerkung zum BGH-Urteil vom 15.4.2010 - I ZR 145/08; MPR 2011, 42
  • Internet-Aktivitäten öffentlich-rechtlicher Rundfunkanstalten, Duncker & Humblot 2007
more less

Education

  • Completed his PhD as a German Academic Scholarship Foundation scholar; topic: broadcasting law
  • 2006: Second state examination in law
  • Trainee lawyer in Hamburg
  • 2001 - 2004: Research assistant for Prof. Dr. Hubertus Gersdorf, University of Rostock
  • LL.M. at Queen Mary University of London as a German Academic Exchange Service scholar
  • 2000: First state examination in law
  • Law studies in Hamburg
more less

Feed

27/03/2024
Cannabis law and legislation in Germany
Medical use The legalisation of cannabis for medical use took place in 2017. It is therefore permitted to grow, sell and import cannabis for medical use in Germany. Pursuant to the German Narcotics Act...
28/03/2023
CMS wins with GE Healthcare in Federal Social Court
Hamburg – On February 22, 2023, the Federal Social Court ruled that a benefit assessment and a price regulation for a medicinal product with a new active ingredient is unlawful for lack of a legal basis...
09/11/2022
Key points paper of the federal government on cannabis legalization
It's getting more concrete: The federal government sets out key points for the planned legalization of recreational cannabis In the coalition agreement, the coalition parties agreed to allow "controlled...
12/05/2022
European Cannabis Conference
The conference will comprise of high-interest panel discussions at the forefront of the growing cannabis sector. The following agenda will be updated with panelists as they are con­firmed. At­tend­ance...
11/03/2022
CMS Germany and Malta Enterprise Corporation sign cooperation and secondment...
CMS Germany and Malta Enterprise Corporation, the Republic of Malta’s economic development agency, signed a comprehensive cooperation and secondment agreement on 4 March 2022. CMS Germany has been...
08/03/2022
CMS Expert Guide to adverse effects of drugs and vaccines
The global pandemic has risen a growing awareness of the risks of adverse effects of drugs and vaccines. This unexpected event has put healthcare professionals in a situation whereby the standard protocols...
07/02/2022
CMS advises Dr Reddy's on acquisition of Nimbus Health
Stuttgart - The Indian stock-listed pharmaceutical group Dr. Reddy's has signed a definite agreement to acquire all shares of Nimbus Health GmbH, a wholesaler specialising in medicinal cannabis. In future...
30/07/2021
CMS advises capiton on investment of top-up single-asset fund in portfolio...
Berlin - Private equity firm capiton has closed a top-up single-asset fund for its fast-growing portfolio company KD Pharma Group (KD Pharma). This top-up fund will provide KD Pharma with the equity financing...
25/03/2021
European Cannabis Conference
The conference will comprise high-interest panel discussions at the forefront of the growing cannabis sector. Key panel topics will include the European Cannabis Landscape, Challenges & Opportunities...
23/11/2020
EU high court confirms CBD is not a narcotic
In a long-awaited ruling, the European Court of Justice (ECJ) clarified that the cannabis active ingredient Cannabidiol (CBD) is not to be classified as a narcotic. France submits question on CBD in e-cigarettes...
26/06/2020
Apotal Group sells online pharmacy’s mail-order business and diabetes arm...
Stuttgart – Company founder Heinz-Peter Fichter and other shareholders have sold the mail-order business of online pharmacy Apotal and its diabetes division to the listed Zur Rose Group of Switzerland...
18/05/2019
INTA Annual Meeting 2019
Several of our partners coming from over 15 different countries, will be at INTA's 2019 Annual Meeting in Boston, USA. To arrange a meeting during INTA, please contact any of our delegates profiled below...